The control of protein solubility is a subject of broad interest. Although several solvent screening methods are available to search for compounds that enhance protein solubilization, their performance is influenced by the intrinsic solubility of the tested protein. We now present a method for screening solubilizing compounds, using an array of N-or C-terminal deletion mutants of the protein. A key behind this approach is that such terminal deletions of the protein affect its aggregation propensity.
| INTRODUCTION
The control of protein solubility is an important subject in physics, chemistry, biology and medicine. For example, the aggregation and precipitation of target proteins represent one of the major bottlenecks in the structural analyses by NMR and X-ray crystallography (Berry et al., 2006; Gryk, Vyas, & Maciejewski, 2010; Walter et al., 2005; Wang, Nema, & Teagarden, 2010) . NMR studies require protein concentrations on the submillimolar order, which are higher than physiological concentrations, and thus, the avoidance of protein aggregation/precipitation often becomes a main consideration in the sample preparation. Protein precipitation also occurs in vivo under certain conditions. The precipitation of specific proteins frequently arises in the brains of patients with neurodegenerative diseases, and these protein aggregates are considered to be potential therapeutic targets (Forman, Trojanowski, & Lee, 2004) .
In such situations, compound screening for enhancing the solubilization of the target proteins has been regarded as a promising approach. For example, Bagby, Tong, and Ikura (2001) reported the use of microdialysis buttons for Genes to Cells YUNOKI et al. screening compounds that inhibit protein precipitation. Lepre and Moore (1998) reported "microdrop screening," which adopts the "hanging drop" crystallization technique to investigate precipitation in solutions composed of the protein sample and various compounds. Bagby, Tong, Liu, Alattia, and Ikura (1997) applied the "microdialysis" method to screen solvents for NMR. More recently, Howe reported the use of the "microbatch under oil method" (Chayen, 1997) , a robotcompatible crystallization method, for the screening of solution conditions (Howe, 2004) . Furthermore, Lindwall and colleagues reported a method of analyzing protein solubility by SDS-polyacrylamide gels, to determine the best buffer for the extraction of an over-expressed protein (Lindwall, Chau, Gardner, & Kohlstaedt, 2000) . Sugiki et al. (2009) proposed the use of fluorescent correlation spectroscopy to capture the invisible aggregation of proteins. One problem with these screening methods is that the performance of the screening is influenced by the intrinsic solubility of the target proteins. Unless the solubility of the protein is appropriate for the screening test, an excess number of solvent conditions will be needed for the screen.
In this study, we propose a method for screening compounds that enhance protein solubilization, using serial deletion mutants of the targeted proteins. In this approach, solvents containing candidate compounds are tested with an array of N-or C-terminal deletion mutants in parallel. The proteinsolubilization activities of the solvents are ranked based on the number of successfully solubilized mutants. Subsequently, the compounds in the highly ranked solvents are assessed in terms of their fractions of mutant solubilization over all cases including the compound, thereby identifying the most appropriate compounds for solubilizing the target protein. The multicomponent screening using serial deletion mutants allows the systematic screening of conditions suitable for an intended purpose and applicable to screening on a large scale.
To test the feasibility of this method, the C-terminal chemokine receptor-binding region of the cytoplasmic protein FROUNT (FNT-C) was selected as the solubilization target in this study. FROUNT interacts with the membraneproximal C-terminal regions of chemokine receptors, CCR2 and CCR5, through FNT-C (Terashima et al., 2005; Toda et al., 2009 ). The intracellular interaction promotes leukocyte migration, and thus, FROUNT represents a promising target for drug development (Esaki et al., 2011 Terashima et al., 2005; Toda et al., 2009 Toda et al., , 2014 .
| RESULTS

| Effects of terminal deletions on the intrinsic solubility of FNT-C
The deletion of a few amino acid residues at the N-or C-terminus of a protein alters its solubility to some extent (Gräslund, Sagemark et al., 2008; Gräslund, Nordlund et al., 2008) . For example, in the study of the PB1 domain of Cdc24, numerous terminal deletion mutants were constructed for sample preparation and a proper construct for structural studies was identified (Ito, Matsui, Ago, Ota, & Sumimoto, 2001; Terasawa et al., 2001; Yoshinaga et al., 2003) . An array of deletion mutants can be constructed efficiently, such as by a polymerase incomplete primer extension cloning method (Klock, Koesema, Knuth, & Lesley, 2008) . In many cases, the solubility of the protein is too low or too high for efficient solubility compound screening. On the one hand, if the solubility of the protein is too low, then visible precipitates of the protein still remain even in the presence of solubilizing compound (Figure 1a [i, iv] ). However, if the solubility of the target protein is too high, then the protein solution appears transparent even in the absence of the solubilizing compounds (Figure 1a [iii, vi] ). In our method, even if the intrinsic solubility of the original target protein is too high or too low, the solubility can be adjusted to an appropriate level so that visible precipitates disappear upon the addition of the solubilizing compound (Figure 1a [ii, v] ). We planned to screen solvent conditions suitable for solubilizing the target protein, using an array of N-or C-terminal deletion mutants of the protein.
Solvents containing different compounds were subjected to the screening test for the array of deletion mutants in parallel, and then, the protein-solubilization activity of each solvent was assessed, based on the number of successfully solubilized mutants (Figure 1b) .
The previously reported amino acid region of FNT-C was designated as mutant A (Toda et al., 2009 ). We also constructed mutant B, based on the results of limited proteolysis of mutant A (Sonoda et al., 2017) . Mutants C-H were created by N-or C-terminal deletions of mutant B, because the terminal deletions often change the protein solubility (Gräslund, Sagemark et al., 2008; Gräslund, Nordlund et al., 2008) . The amino acid regions of the eight mutants are as follows: mutant A: 493-656, mutant B: 532-656, mutant C: 534-656, mutant D: 537-656, mutant E: 532-650, mutant F: 532-654, mutant G: 532-653 and mutant H: 532-652 (Figure 2) .
A prerequisite for our screening method is that deletions of terminal residues in the target protein actually change the protein solubility. Based on the quality of the NMR spectra of the eight mutants, the mutants were ranked and then mutants A, B, E and H were selected as representatives in each rank (Figure 3 ). The spectral qualities were markedly different between the four mutants. In terms of the uniformity of peak intensities, mutant E was best, followed by mutant H, mutant B and mutant A in that order. However, the pattern of the dispersed peaks was preserved between the four mutants, suggesting that the folded structures included in the FNT-C region are preserved. As nonuniform peak intensities in the 1 H-15 N HSQC spectra, such as in those of mutants A and B,
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are typically indicative of partial aggregation of the protein, the results indicated that the deletion mutants differ in their solubilities.
| Solvent screening using an array of deletion mutants
For the screening shown in Figure 1 , a hanging drop method with commercial crystallization kits was applied for universal use. Each of the eight deletion mutants was mixed and incubated with the 192 solution conditions in the commercial crystallization kits, to select the conditions that suppress visible precipitation. Among the eight mutants, the numbers of solubilizing solvents were different (i.e., mutant A: 17, mutant B: 19, mutant C: 3, mutant D: 5, mutant E: 13, mutant F: 31, mutant G: 20 and mutant H: 33), reflecting their different solubilities ( Figure 4 ). In the present case, four solvent conditions solubilized four mutants (orange in Figure 4 ) and one condition solubilized five mutants (red in Figure 4 ), and these solvents are presumably suitable for the solubilization of FNT-C. It should be pointed out that, if the solvent screening had been carried out using only a single mutant, then the screening would have failed to identify the solvent conditions with high solubilization activities for FNT-C. For example, if the screening had been carried out using only mutant H, as many as 33 solvent conditions would have been identified. Conversely, if only mutant C had been used, as few as three solvent conditions would have been identified, in which suitable compounds, suppressing the precipitation of most of the mutants, were not included.
Subsequently, we focused on the compounds in the solvents that solubilized four or five mutants of FNT-C. For example, the Kit 2-39 solvent (red in Figure 4 ), which solubilized five mutants of FNT-C, contained 1,6-hexanediol, and thus, we assumed that 1,6-hexanediol represents a candidate compound for suppressing the precipitation of FNT-C. To assess the solubilization ability of such a compound, the "clear rate" was defined as a hit (solubilized) rate among the tests in the presence of the target compound. For example, 1,6-hexanediol was included in the Kit 2-11, Kit 2-19 and Kit 2-39 solvents. Therefore, 1,6-hexanediol was included in 24 solvent/mutant pairs (i.e., three solvents × eight mutants). Among the trials, solubilizations of the tested mutants were observed in eight cases (i.e., Kit 2-11: no mutants, Kit 2-19; 3 mutants, Kit 2-39; 5 mutants), which amounts to the clear rate of 33%. The clear rate was assessed for other compounds in the Kit 2-39 solvent and those in the solvents that solubilized four mutants of FNT-C (yellow in Figure 4) . As a result, 1,6-hexanediol and polyethylene glycol monomethyl ether (PGME) 550 exhibited the highest and second highest clear rates (i.e., 1,6-hexanediol: 33%, PGME: 25%), respectively ( Table 1) . The problem with PGME 550 is its large molecular weight. When a number of PGME molecules bind to FNT-C, the NMR signals are substantially broadened, thereby making it difficult to perform NMR analyses. We thus omitted PGME from the candidate compounds and concluded that 1,6-hexanediol was the best compound available for suppressing the precipitation of FNT-C.
| NMR assessments of the interactions between FNT-C and 1,6-hexanediol
Using NMR, the ability of 1,6-hexanediol to bind to the target protein FNT-C was analyzed. First, a saturation transfer difference (STD)-NMR spectrum of 1,6-hexanediol was measured in the absence and presence of FNT-C (mutant B). On the 1 H NMR spectra, the protons of 1,6-hexanediol gave rise to signals resonating at 1.4, 1.6 and 3.7 ppm (Figure 5a,b) . In this STD experiment, a selective radiofrequency pulse was applied at 0 ppm. As there was no signal of 1,6-hexanediol around 0 ppm, the signals of 1,6-hexanediol were almost unaffected by the irradiation, and thus, the signal intensities of 1,6-hexanediol in the STD spectrum was negligibly small in the absence of FNT-C (data not shown). FNT-C has methyl 1 H signals resonating near 0 ppm, and thus, the irradiation at 0 ppm caused the saturation of the methyl signals. Remarkably, the signal intensities of 1,6-hexanediol were reduced approximately 5% by the irradiation at 0 ppm ( Figure 5b) . As a result, the STD signals of 1,6-hexanediol were detected. It was conceivable that 1,6-hexanediol bound to FNT-C and the saturation was transfer from FNT-C to 1,6-hexanediol.
Next, 1 H-15 N TROSY-HSQC spectra were recorded on 2 H-and 15 N-labeled FNT-C in the absence and presence of 1,6-hexanediol, and the two spectra were compared. As a result, marginal, but significant, changes in chemical shifts upon the addition of 1,6-hexanediol were observed for a number of peaks (Figure 5c ), supporting the proposal that 1,6-hexanediol interacts with FNT-C. As the magnitude of the chemical shift perturbation was marginal, the overall conformation of FNT-C was preserved in the presence of 1,6-hexanediol, suggesting that the functional activity of FNT-C was not affected by 1,6-hexanediol. 1,6-Hexanediol potentially mediates both hydrophilic and hydrophobic interactions, considering its chemical structure (Figure 5a ). NMR titration analyses indicated that both hydrophobic and hydrophilic residues of FNT-C were involved in the 1,6-hexanediol-binding (to be described elsewhere).
| Solubilization ability of 1,6-hexanediol, as showed by a dynamic light scattering analysis
Next, we examined whether the binding of 1,6-hexanediol to FNT-C actually enhances its solubilization. Assuming a globular structure, the hydrodynamic radius (R h ) of mutant B of FNT-C was evaluated by dynamic light scattering (DLS) in the absence and presence of 1,6-hexanediol. 
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Interaction between mutant B of FNT-C and 1,6-hexanediol, as probed by NMR experiments. (a) Chemical structure of 1,6-hexanediol. (b) One-dimensional 1 H, off-resonance, on-resonance and STD NMR spectra of a solution containing 50 mM 1,6-hexanediol and 0.5 mM of the mutant B of FNT-C. In the one-dimensional 1 H spectrum, the vertical scale is substantially magnified to clarify the presence of methyl signals of mutant B near 0 ppm (indicated by an arrow). The off-resonance and on-resonance spectra were recorded with selective irradiation at 30 ppm and 0 ppm, respectively. The STD spectrum was generated by subtracting the on-resonance spectrum from the off-resonance spectrum. The vertical scales of the on-and off-resonance spectra are identical and that of the STD is eightfold larger than those of the on-and off-resonance spectra. The autocorrelation functions of mutant B in the absence and presence of 1,6-hexanediol differed by 0.014 at the time of 10 μs (Figure 6a ). This difference was significantly larger than the error sizes in the absence and presence states (e.g., less than 0.005), demonstrating that the two autocorrelation functions were significantly different (Figure 6c,d) . In the absence of 1,6-hexanediol, mutant B exhibited a bimodal size distribution, composed of a major peak with an R h of 3.5 nm and a minor peak with an R h of around 60 nm (Figure 6b, black) . As the R h value expected for a monomer of mutant B is about 2 nm, even the major peak is expected to represent oligomers or aggregates and the minor peak could be higher-order oligomers or large aggregates. In the presence of 1,6-hexanediol, FNT-C also exhibited a bimodal distribution, but the R h values of the major and minor peaks decreased to 3.3 nm and 40 nm, respectively (Figure 6b , orange). These decreases in the R h values suggested that the aggregation propensity of FNT-C is mitigated by the addition of 1,6-hexanediol.
| DISCUSSION
The control of protein precipitation is an important subject in many scientific areas. In NMR and X-ray crystallographic studies of proteins, for example, the avoidance of protein aggregation and precipitation represents the most challenging subject to address. In many cases, the target proteins undergo nonfunctional aggregation that simply impedes the structural analysis of the proteins, and thus, the choices of the construct boundaries and the solvent conditions are important considerations. If the poor solubility of proteins is attributable to their N-and C-termini, then their solubility can be improved by optimizing the construct boundaries of the proteins to some extent. In many cases, however, the inner parts distal from the terminal regions are also responsible for the aggregation of proteins. Even in such situations, it is possible to enhance protein solubility by optimizing the solution conditions. Our screening method allows for the efficient identification of solubilizing compounds that can suppress the aggregation occurring through nonboundary regions and thus has the high potential to achieve the solubilization of a wide variety of proteins.
There are options in our screening method. For example, multicomponent screening kits were used in the present study. In the multicomponent screening kits, each test solution contains several compounds and thus a large number of compounds can be tested. Instead of such multicomponent screening kits, single component or additive screening kits can also be used in our screening strategy. In those cases, proper solubilizing compounds may be identified in a straightforward manner. However, the number of screening drops will increase. Another possible option is to vary the concentration of compounds by changing the ratio of the protein solution to the test solution. In this option, concentration dependence of the solubilizing effect of each compound can be identified, and additional solubilizing compounds may be successfully identified.
In terms of addressing the solubility problem of proteins, an advantage of our method is that the construct of the natural sequence can be used as is. Even if the target protein is fused to a solubility-enhancement tag, the natural sequence segment often remains insoluble. In addition, the attached tag may interact with the natural sequence segment. However, a disadvantage of our method is that the use of multiple deletion mutants proportionally increases the number of drops to be tested.
We envisage the application of this method to subjects in other areas, such as drug development. Detailed analyses of the interactions between the screened compounds and the target proteins may provide clues toward the development of potent drugs targeted to the proteins. If the screened compound is small and the location of the contact site for the compound is different from those of other compounds on the protein surface, then it can be used as a fragment within the framework of fragment-based drug discovery (Murray, Verdonk, & Rees, 2012) . As our screening method is applicable to screening on a larger scale, it is a promising approach for identifying fragments for new drugs. The compounds suppressing the oligomerization/fibrillization of specific proteins may be used as therapeutic strategies for the treatment of neurodegenerative diseases (e.g., Alzheimer's disease and Lewy body dementia). The brains of patients with these neurodegenerative diseases often contain oligomers/fibrils of specific proteins (e.g., amyloid β, tau and α-synuclein) (Forman et al., 2004) . If the oligomerization/fibrillization of the proteins is suppressed by the screened compounds, then the pathogenic protein will remain monomeric and be cleared efficiently.
| CONCLUSION
In this study, we presented a screening method to identify compounds that enhance protein solubility, using an array of N-or C-terminal deletion mutants of the target protein. This screening method is widely applicable to small-to large-sized screening tests for improving their performance. In many areas of basic and applied sciences, the control of protein solubility is an important subject to be addressed. We hope that our method provides opportunities to expand the scope of scientific research.
| EXPERIMENTAL PROCEDURES
| Materials
Restriction enzymes were purchased from Toyobo Co., Ltd. PrimeStar DNA polymerase was purchased from Takara Bio, Inc. SYBR ® Safe DNA gel stain was purchased from Invitrogen.
Molecular weight standards for SDS-PAGE were purchased from Bio-Rad. Other reagents were purchased from Nacalai Tesque, Inc., and Wako Chemicals, unless otherwise noted.
| Construction of expression vectors
The DNA fragments encoding human FROUNT, amino acids 493-656 (A), 532-656 (B), 534-656 (C), 537-656 (D), 532-650 (E), 532-654 (F), 532-653 (G) and 532-652 (H) were amplified by polymerase chain reaction and cloned inframe into the pGEX-4T-3 DNA vector, between the BamH I and Xho I sites, using the procedure as described (Sonoda et al., 2017) .
| Expression and purification of FNT-C
Expression and purification were performed in the manners as described previously (Sonoda et al., 2017) . FNT-C was fused to a glutathione S-transferase (GST) tag. GST-FNT-C was expressed in E. coli BL21 cells (Merck Millipore), as a soluble protein. The cells were lysed, and the GST-FNT-C was purified by chromatography on a glutathione-Sepharose 4B column (GE Healthcare). GST was excised from GST-FNT-C with thrombin protease (ILS) in the column. FNT-C was further purified by chromatography on a Q Sepharose Fast Flow column (GE Healthcare), followed by gel filtration chromatography on a Superdex 200 column (GE Healthcare).
| Screening
The screen was prepared using the hanging drop method, with a 24-well VDX plate with pre-applied sealant and siliconized glass cover slips (Hampton Research Corp. , pH 7.5) was dispensed onto the glass cover slips and was mixed with 0.5 μl of reservoir solution by gently drawing and expelling the solution in the pipette tip. The glass slips were then inverted and sealed onto the wells, using the sealant applied to the VDX plate. The concentrations of the mutant protein solutions were approximately 2 mg/ml. The plates were incubated at 20°C for 2 months. The precipitates in the drops were observed by microscopy.
| NMR spectroscopy
NMR analyses were performed on a Bruker 600-MHz Avance III spectrometer with a TXI cryogenic probe, unless stated otherwise. All spectra were processed using TopSpin 2.1 (Bruker BioSpin) and NMRPipe (Delaglio et al., 1995) . 1 H-15 N HSQC experiments were performed with 50 μM solutions of the uniformly 15 N-labeled mutants A, B, E and H of FNT-C, in 20 mM Tris-HCl, 150 mM NaCl, pH 7.5 and 1 mM DTT, at 25°C. The STD experiments were performed with a Bruker 500-MHz Avance III spectrometer equipped with a TCI cryogenic probe using a solution sample containing 50 mM of unlabeled 1,6-hexanediol and 0.5 mM of unlabeled mutant B in 20 mM Tris-HCl, 50 mM NaCl, pH 7.5, 1 mM perdeuterated DL-1,4-DTT (D10, 98%) and 100% D 2 O at 35°C. Selective saturation of mutant B of FNT-C was performed at 0 ppm and 30 ppm for on-resonance and off-resonance spectra, respectively, using Gaussian-shaped pulses.
For the chemical shift perturbation experiment, 1 H-15 N TROSY-HSQC spectra were recorded on 50 μM of uniformly 2 H-and 15 N-labeled mutant B, dissolved in 20 mM Tris-HCl containing 50 mM NaCl, pH 7.5, 1 mM DTT and 5% D 2 O, in the presence and absence of 50 mM unlabeled 1,6-hexanediol at 25°C.
| Dynamic light scattering measurements
Dynamic light scattering data of mutant B of FNT-C were collected with a DynaPro instrument (Wyatt Technology). The protein sample (50 μM) was prepared by adding an equal volume of sodium phosphate buffer to a solution of mutant B in Tris-HCl buffer, resulting in a solution containing 50 μM mutant B, 50 mM sodium phosphate, 10 mM Tris-HCl and 1 mM DTT (pH 6.2). The solution was filtered through a 0.02-μm filter. The hydrodynamic radius (R h ) was calculated using the Dynamics V5 software, assuming a globular species shape.
